Trials / Completed
CompletedNCT04971031
A Clinical Trial to Assess Subjects With Dry Eye Disease.
A Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 158 (actual)
- Sponsor
- Aldeyra Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Reproxalap Ophthalmic Solution (0.25%) | Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days. |
| DRUG | Vehicle Ophthalmic Solution | Vehicle Ophthalmic Solution administered 7 times over two consecutive days. |
Timeline
- Start date
- 2021-06-15
- Primary completion
- 2021-09-08
- Completion
- 2021-09-08
- First posted
- 2021-07-21
- Last updated
- 2025-02-24
- Results posted
- 2023-03-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04971031. Inclusion in this directory is not an endorsement.